Boehringer Ingelheim Venture Fund has participated in a $23.8m round for the antibody developer that was co-led by V-Bio Ventures and Advent France Biotechnology.

Agomab Therapeutics, a Belgium-based developer of tissue regeneration technology, has secured €21m ($23.8m) in series A funding from a consortium including pharmaceutical firm Boehringer Ingelheim. The round was co-led by venture capital fund V-Bio Ventures and life sciences VC firm Advent France Biotechnology and included Omnes and Pontifax, while Boehringer Ingelheim invested through corporate venturing…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.